Can Butyrate offer a novel approach to mitigate the pathology of AD?
This investigation represents the initial confirmation of butyrate as an amyloid beta inhibitor across various Alzheimer's disease (AD) models. The subsequent steps involve determining the levels of butyrate at different stages of AD by analyzing fecal samples and conducting tests to assess its therapeutic efficacy.
Authors
- Ian Martins (ORCID: https://orcid.org/0000-0002-2390-1501)
- Prashant Bharadwaj (ORCID: https://orcid.org/0000-0003-4361-9906)
- Ralph N. Martins (ORCID: https://orcid.org/0000-0002-4828-9363)
- Warnakulasuriya Mary Ann Dipika Binosha Fernando (ORCID: https://orcid.org/0000-0002-8364-7808)
- Uththara Senerath
Institutions
- Edith Cowan University (AU)
- Cooperative Research Centre for Mental Health (AU)
- Australian Alzheimer’s Research Foundation (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.088636
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00